NAS:MLNT (USA) Also trade in: Germany

Melinta Therapeutics Inc

$ 2.98 0 (0%)
Volume: 355,957 Avg Vol (1m): 483,572
Market Cap $: 35.10 Mil Enterprise Value $: 71.96 Mil
P/E (TTM): 0.00 P/B: 0.20
Earnings Power Value -132.55
Net Current Asset Value -9.9
Tangible Book -4.29
Projected FCF -59.05
Median P/S Value 361.27
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.76
Cash-To-Debt ranked lower than
76.62% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
MLNT: 0.76
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.17, Med: 6.87, Max: 10000
Current: 0.76
0.17
10000
Equity-to-Asset 0.38
Equity-to-Asset ranked lower than
71.04% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
MLNT: 0.38
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -17.64, Med: 0.72, Max: 0.82
Current: 0.38
-17.64
0.82
Debt-to-Equity 0.87
Debt-to-Equity ranked lower than
62.80% of 500 companies
in the Biotechnology industry.
Industry Max: 35.66, Med: 0.28, Min: 0.01
MLNT: 0.87
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -0.24, Med: 0.17, Max: 0.87
Current: 0.87
-0.24
0.87
Debt-to-EBITDA -1.58
Debt-to-EBITDA ranked lower than
100.00% of 196 companies
in the Biotechnology industry.
Industry Max: 1208.58, Med: 2.04, Min: 0.01
MLNT: -1.58
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.58, Med: -0.56, Max: -0.26
Current: -1.58
-1.58
-0.26
Piotroski F-Score 3
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -2.61
DISTRESS
GREY
SAFE
Beneish M-Score -0.59
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -49.44%
WACC 45.79%

Profitability & Growth : 3/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -116.26
Operating Margin ranked lower than
59.34% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
MLNT: -116.26
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -549.34, Med: -311.74, Max: -116.26
Current: -116.26
-549.34
-116.26
Net Margin % -161.27
Net Margin ranked lower than
55.93% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
MLNT: -161.27
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -576.41, Med: -289.57, Max: -161.27
Current: -161.27
-576.41
-161.27
ROE % -72.63
ROE ranked lower than
66.63% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
MLNT: -72.63
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -119.81, Med: -100.19, Max: -70.51
Current: -72.63
-119.81
-70.51
ROA % -32.72
ROA ranked lower than
51.57% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
MLNT: -32.72
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -191.64, Med: -60.35, Max: -32.72
Current: -32.72
-191.64
-32.72
ROC (Joel Greenblatt) % -5626.96
ROC (Joel Greenblatt) ranked lower than
81.37% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
MLNT: -5626.96
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -74400, Med: -25250, Max: -3803.63
Current: -5626.96
-74400
-3803.63
3-Year Total EBITDA Growth Rate -9.00
3-Year EBITDA Growth Rate ranked lower than
72.94% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
MLNT: 37.1
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -101.6, Med: 37.1, Max: 67.5
Current: 37.1
-101.6
67.5
3-Year EPS w/o NRI Growth Rate 31.80
3-Year EPS w/o NRI Growth Rate ranked lower than
85.85% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
MLNT: 31.8
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: -129.4, Med: 31.8, Max: 69.3
Current: 31.8
-129.4
69.3

» MLNT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-07)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:MLNT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:CLDX XKRX:215380 OSTO:ACTI TSE:4570 TSE:4583 ROCO:3205 ASX:BNO NAS:HOTH TSE:4575 TSX:PMN NAS:INNT OTCPK:BCDA ASX:BOT NAS:MBRX ASX:MDC NAS:PTI NAS:ENTX NAS:AZRX OSTO:ACE NAS:PLXP
Traded in other countries 9C1B.Germany
Address 300 George Street, Suite 301, New Haven, CT, USA, 06511
Melinta Therapeutics Inc, formerly Cempra is a clinical-stage biotechnology company that develops differentiated antibiotics for acute care and community settings. The company's goal is to develop treatments for bacterial infectious diseases, particularly respiratory tract infections and staphylococcal infections. The company is particularly focused on treating community-acquired bacterial pneumonia, as well as gonorrhea and other indications. The company operates three segments, including contract research, license, and supply. Cempra generates most of its revenue through its contract research and license segments.

Ratios

Current vs industry vs history
PB Ratio 0.20
PB Ratio ranked higher than
97.51% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
MLNT: 0.2
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 0.19, Med: 27.12, Max: 101.63
Current: 0.2
0.19
101.63
PS Ratio 0.33
PS Ratio ranked higher than
85.54% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
MLNT: 0.33
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 0.01, Med: 40.42, Max: 2871.77
Current: 0.33
0.01
2871.77
EV-to-EBIT -0.63
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
MLNT: -0.63
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -26.3, Med: -5.2, Max: 9
Current: -0.63
-26.3
9
EV-to-EBITDA -0.74
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
MLNT: -0.74
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -26.3, Med: -5.2, Max: 9.5
Current: -0.74
-26.3
9.5
EV-to-Revenue 0.75
EV-to-Revenue ranked higher than
76.78% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
MLNT: 0.75
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -99999999.99, Med: 27.1, Max: 1235657
Current: 0.75
-99999999.99
1235657
Current Ratio 1.40
Current Ratio ranked lower than
76.54% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
MLNT: 1.4
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.64, Med: 9.05, Max: 30.34
Current: 1.4
0.64
30.34
Quick Ratio 1.06
Quick Ratio ranked lower than
76.82% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
MLNT: 1.06
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.64, Med: 9.05, Max: 30.34
Current: 1.06
0.64
30.34
Days Inventory 329.73
Days Inventory ranked lower than
83.37% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
MLNT: 329.73
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 231.88, Med: 231.88, Max: 329.73
Current: 329.73
231.88
329.73
Days Sales Outstanding 55.01
Days Sales Outstanding ranked higher than
61.08% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
MLNT: 55.01
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 55.01, Med: 80.08, Max: 82.52
Current: 55.01
55.01
82.52
Days Payable 74.56
Days Payable ranked higher than
98.69% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
MLNT: 74.56
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 74.56, Med: 149.04, Max: 149.04
Current: 74.56
74.56
149.04

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -1.40
3-Year Share Buyback Rate ranked lower than
82.26% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
MLNT: -1.4
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -592.4, Med: -23.8, Max: -1.4
Current: -1.4
-592.4
-1.4

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.01
Price-to-Median-PS-Value ranked higher than
97.49% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
MLNT: 0.01
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.01, Med: 1.13, Max: 71.07
Current: 0.01
0.01
71.07
Earnings Yield (Joel Greenblatt) % -158.54
Earnings Yield (Greenblatt) ranked lower than
80.76% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
MLNT: -158.54
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -165.32, Med: -13.6, Max: 20.6
Current: -158.54
-165.32
20.6

More Statistics

Revenue (TTM) (Mil) $ 95.67
EPS (TTM) $ -15.68
Beta 3.16
Volatility % 85.96
52-Week Range $ 2.7 - 46
Shares Outstanding (Mil) 11.78

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 3
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y